X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PFIZER - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PFIZER DIVIS LABORATORIES/
PFIZER
 
P/E (TTM) x 18.2 24.2 75.2% View Chart
P/BV x 3.9 3.9 102.4% View Chart
Dividend Yield % 1.6 0.8 186.7%  

Financials

 DIVIS LABORATORIES   PFIZER
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
PFIZER
Mar-16
DIVIS LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2,4842,724 91.2%   
Low Rs9181,611 57.0%   
Sales per share (Unadj.) Rs142.3440.9 32.3%  
Earnings per share (Unadj.) Rs41.948.7 86.0%  
Cash flow per share (Unadj.) Rs46.375.8 61.2%  
Dividends per share (Unadj.) Rs10.0015.00 66.7%  
Dividend yield (eoy) %0.60.7 85.0%  
Book value per share (Unadj.) Rs161.5462.9 34.9%  
Shares outstanding (eoy) m265.4745.75 580.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.04.9 243.2%   
Avg P/E ratio x40.644.5 91.2%  
P/CF ratio (eoy) x36.728.6 128.3%  
Price / Book Value ratio x10.54.7 224.9%  
Dividend payout %23.930.8 77.5%   
Avg Mkt Cap Rs m451,52599,163 455.3%   
No. of employees `0003.72.9 128.3%   
Total wages/salary Rs m3,6492,758 132.3%   
Avg. sales/employee Rs Th10,184.46,981.7 145.9%   
Avg. wages/employee Rs Th984.1954.5 103.1%   
Avg. net profit/employee Rs Th2,998.5771.1 388.9%   
INCOME DATA
Net Sales Rs m37,76420,170 187.2%  
Other income Rs m848857 99.0%   
Total revenues Rs m38,61221,028 183.6%   
Gross profit Rs m14,1384,310 328.0%  
Depreciation Rs m1,1821,239 95.4%   
Interest Rs m235 446.2%   
Profit before tax Rs m13,7813,923 351.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m2,6621,794 148.4%   
Profit after tax Rs m11,1192,228 499.1%  
Gross profit margin %37.421.4 175.2%  
Effective tax rate %19.345.7 42.2%   
Net profit margin %29.411.0 266.6%  
BALANCE SHEET DATA
Current assets Rs m30,94716,299 189.9%   
Current liabilities Rs m5,1957,594 68.4%   
Net working cap to sales %68.243.2 158.0%  
Current ratio x6.02.1 277.5%  
Inventory Days Days11765 178.9%  
Debtors Days Days8526 330.6%  
Net fixed assets Rs m17,0278,622 197.5%   
Share capital Rs m531458 116.0%   
"Free" reserves Rs m42,34120,722 204.3%   
Net worth Rs m42,87721,180 202.4%   
Long term debt Rs m525 18.8%   
Total assets Rs m49,68429,137 170.5%  
Interest coverage x595.0755.5 78.8%   
Debt to equity ratio x00 9.3%  
Sales to assets ratio x0.80.7 109.8%   
Return on assets %22.47.7 292.6%  
Return on equity %25.910.5 246.5%  
Return on capital %32.219.0 169.5%  
Exports to sales %85.30.1 143,312.4%   
Imports to sales %22.917.5 131.1%   
Exports (fob) Rs m32,19812 268,316.7%   
Imports (cif) Rs m8,6543,526 245.5%   
Fx inflow Rs m32,27052 62,479.1%   
Fx outflow Rs m8,775140 6,268.4%   
Net fx Rs m23,496-88 -26,600.2%   
CASH FLOW
From Operations Rs m10,3793,436 302.1%  
From Investments Rs m-4,135-6,991 59.1%  
From Financial Activity Rs m-6,241-619 1,008.6%  
Net Cashflow Rs m3-4,174 -0.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.8 7.5 157.3%  
FIIs % 19.0 4.9 387.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 23.7 72.6%  
Shareholders   31,796 85,207 37.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Consumer Durables Stocks Drag(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are trading above the dotted line. Except stocks in the consumer durables sector.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 23, 2017 02:19 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - J.B.CHEMICALS COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS